Treatment for Respiratory Syncytial Virus Infections

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
University of California San Francisco, San Francisco, CA
Respiratory Syncytial Virus Infections+1 More
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether azithromycin might be helpful for people with respiratory syncytial virus (RSV) infections.

See full description

Eligible Conditions

  • Respiratory Syncytial Virus Infections

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Respiratory Syncytial Virus Infections

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome and 2 secondary outcomes in patients with Respiratory Syncytial Virus Infections. Measurement will happen over the course of At ICU discharge (Approximately 1 week).

Week 1
Length of ICU stay
Week 1
Duration of oxygenation
Week 2
Length of Hospitalization

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Respiratory Syncytial Virus Infections

Trial Design

2 Treatment Groups

AZM 20mg/kg Treatment Group
1 of 2
Control Group
1 of 2
Active Control
Non-Treatment Group

This trial requires 370 total participants across 2 different treatment groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.

AZM 20mg/kg Treatment Group
Drug
Control Group
Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at discharge (approximately 2 weeks)
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly at discharge (approximately 2 weeks) for reporting.

Who is running the study

Principal Investigator
M. K.
Michele Kong, PI
University of Alabama at Birmingham

Closest Location

University of California San Francisco - San Francisco, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and younger. There are 4 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
requiring respiratory support, which means that the person needs help breathing, either through a machine or with a device that provides continuous positive airway pressure (CPAP). show original
The age range for eligibility is from neonates to two years old, and the child must have been discharged home from the hospital after their birth if they are less than one week old. show original
The patient is admitted to the pediatric ICU with a confirmed diagnosis of RSV infection show original
The study required enrollment within 48 hours of ICU admission and placement on intensive respiratory support. show original

Patient Q&A Section

Can respiratory syncytial virus infections be cured?

"Respiratory syncytial virus infections can be cured following appropriate immunologic control of the disease. Respiratory syncytial virus can be one of the most difficult and disabling and the most likely persistent and recurrent serious illnesses to be eradicated." - Anonymous Online Contributor

Unverified Answer

What are the signs of respiratory syncytial virus infections?

"Paediatricians should be familiar with the signs and symptoms of RSV disease and the identification of an infant with possible RSV disease is important. These include fever, difficulty breathing, fast, shallow breathing and wheezing. Infants with a low-grade illness, such as a mild respiratory tract infection may not present with these characteristics. A chest X-ray may be helpful but should only be done if clinical suspicion of pneumonia exists. Positive-stained respiratory secretions on aspiration, such as rhinorrhea, erythema nodosum, or keratoconjunctivitis sicca should be treated for RSV infection." - Anonymous Online Contributor

Unverified Answer

What are common treatments for respiratory syncytial virus infections?

"This is the first study which summarizes the most commonly used medical treatments for RSV infections in Denmark. There are only a few studies in which the prevalence of RSV infection is known, and RSV is most commonly treated with antibiotics. Although it is difficult to tell if a patient is really sick because of the RSV infection, it helps to administer antibiotics." - Anonymous Online Contributor

Unverified Answer

How many people get respiratory syncytial virus infections a year in the United States?

"Asymptomatic infections of respiratory syncytial virus occur frequently and are a public health problem. There are significant regional differences in the age at infection, which may be related to ethnicity, socioeconomic status, and other factors. The impact of asymptomatic infections, if untreated, may exceed the true severity of an outbreak." - Anonymous Online Contributor

Unverified Answer

What causes respiratory syncytial virus infections?

"Respiratory syncytial virus can be isolated from more than 90% of the young children that are hospitalized for wheezing. In addition to the RSV genome being isolated more frequently in the summer than in the winter, RSV seroprevalence in children with wheezing is significantly increased in cases with chronic bronchiolitis or asthma. These data show that RSV plays a causal role in the development of respiratory infections in children. Given our current inability to adequately treat the disease in infants, RSV and respiratory syndromes are an important area for further investigation of respiratory physiology." - Anonymous Online Contributor

Unverified Answer

What is respiratory syncytial virus infections?

"RSV infections are the most common upper respiratory infections worldwide. They cause the most hospitalizations, and may be responsible for much of the deaths of infants between 1 and 24 months of age. The epidemiological features of RSV vary by country according to the pattern of transmission: in Europe RSV is a common infection in the winter, often leading to the development of disease. In North America and some parts of Australia, RSV tends to be a sporadic epidemic with the cold season preceding the seasonal peaks of disease. However, in many countries, including most parts of Europe, and even in North America and South Africa, most cases of illness are seen in the spring, and outbreaks may be very severe." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of treatment?

"Both groups (with and without adverse events) experienced the common side effects of Finastrem. However, there were significantly more common adverse events in the Finastrem group." - Anonymous Online Contributor

Unverified Answer

What are the latest developments in treatment for therapeutic use?

"The last 10 years have produced a significant advancement in the treatment of pleural effusion. Improvements in imaging have increased the ability to more accurately estimate pleural space and lung volume, thus lowering the need for needle aspiration and lavage during surgical procedures such as VATS and PP. Parenteral fluid administration was shown to be a very promising new therapeutic option for pleural effusions. The most common cause of pleural effusion in children is adenoviral infection. Advantages of this new therapy in the treatment of pleurisy include fewer complications and faster healing of the child's lung. The use of steroids, antibiotics, and other medications may not have the same effects as therapeutic fluid administration to treat pleural effusions." - Anonymous Online Contributor

Unverified Answer

Does respiratory syncytial virus infections run in families?

"Although this is based on a very small number of families and there are some selection-associated factors, the results are consistent with a high heritability of RSI. A plausible explanation for the association between RSV and RSI could be the influence of genetic or other modifiers, with epistatic interaction between gene x infection being important for susceptibility or outcome. Understanding this mechanism may lead to better prevention, timely diagnosis and treatment, and improved control." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of respiratory syncytial virus infections?

"RSV infections are common; the primary cause is in children of all ages including young adults. Most RSVs are acquired the following ways: through contact with persons with RSV illness or contamination of the health care setting." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for respiratory syncytial virus infections?

"Clinicians and parents have some degree of bias toward who is right for clinical trials for RSV infections. Clinicians have similar attitudes in their evaluations when comparing treatment recommendations and their own experiences with treatment. Parents have more bias for younger children's treatment requirements. Clinicians should consider children below 6 months of age for RSV treatment trials in addition to current clinical practice guidelines. Clinicians should consider children who are hospitalized for respiratory disease. Parents should consider older children for clinical trials of systemic therapies." - Anonymous Online Contributor

Unverified Answer

Is treatment typically used in combination with any other treatments?

"Treatment for RSV and/or RV infections is used commonly. Patients treated with combinations of antiviral agents usually also receive corticosteroid therapy. This can lead to increased hospitalizations. Treatment with multiple medications can increase risks." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Respiratory Syncytial Virus Infections by sharing your contact details with the study coordinator.